Мировой рынок ламеллярного ихтиоза — тенденции отрасли и прогноз до 2028 года

Анализ рынка и идеи: глобальный рынок пластинчатого ихтиоза

Ожидается, что рынок ламеллярного ихтиоза будет расти в прогнозируемом периоде с 2021 по 2028 год. Data Bridge Market Research анализирует, что рынок растет со среднегодовым темпом роста 5,60% в указанный выше период прогнозирования исследования. Рост младенческих показателей и увеличение числа сопутствующих симптомов, включая депрессию и другие.

Технологические достижения и доступность возмещения расходов на медицинские устройства также стимулируют рост рынка. Более того, растущие исследования и разработки, наличие перспективных методов лечения и растущие расходы на здравоохранение являются возможностями для роста рынка. Однако побочные эффекты, связанные с вариантами лечения и строгой нормативной базой, среди прочего, могут помешать глобальному рынку пластинчатого ихтиоза.

Пластинчатый ихтиоз — это генетическое заболевание кожи. Сообщается, что оно поражает людей с рождения. У пациентов, страдающих пластинчатым ихтиозом, кожа на ладонях и подошвах ног становится очень толстой, кроме того, кожа становится красной, сухой и грубой. Пластинчатый ихтиоз можно диагностировать с помощью метода пренатальной диагностики, биопсии кожи, ультразвукового исследования и других методов. Для лечения пластинчатого ихтиоза показаны системная терапия, глазная терапия , местная терапия и операции. Системная терапия, используемая для лечения пластинчатого ихтиоза, включает пероральные ретиноиды, в том числе этретинат, лиарозол, изотретиноин и другие. Глазная терапия, предлагаемая для лечения пластинчатого ихтиоза, включает карбоксиметилцеллюлозу натрия, вазелин и минеральное масло и другие. Мази, содержащие салициловую кислоту, ретиноевую кислоту и другие, используются в качестве местной терапии для лечения пластинчатого ихтиоза. Рубцовый эктропион, развившийся у пациентов, страдающих пластинчатым ихтиозом, можно лечить с помощью аппарата Apligraf — эквивалента человеческой кожи.

The infant population subjected to heredity diseases including lamellar ichthyoses is increasing worldwide. This patient population are largely dependent upon the advanced diagnostic and treatment options and hence expected to provide market with the lucrative growth. It is also estimated that lamellar ichthyosis market is growing with the CAGR of 5.60% in 2020.

This lamellar ichthyosis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Lamellar Ichthyosis Market Scope and Market Size

Lamellar ichthyosis market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of diagnosis, the lamellar ichthyosis market is segmented into prenatal diagnosis, immunohistochemistry, skin biopsy and others.
• On the basis of treatment, the lamellar ichthyosis market is segmented into petrolatum-based creams and ointments, artificial tears, retinoid, others.
• On the basis of route of administration, the lamellar ichthyosis market is segmented into oral, topical and others.
• On the basis of end-users, the lamellar ichthyosis market is segmented into clinics, hospitals, diagnostic centers and others.
• On the basis of distribution channel, the lamellar ichthyosis market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.

Lamellar ichthyosis Market Country Level Analysis

Lamellar ichthyosis market is analysed and market size information is provided by country, treatment, product, site, end-users and distribution channel as referenced above.

The countries covered in the lamellar ichthyosis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the increasing prevalence of lamellar ichthyoses and increasing funding activities by U.S FDA for accelerating the research activities targeting rare diseases. Europe is also expected to the grow due to rising initiative by regulatory agencies and rising number of orphan drug designation to drug manufactured for rare disease treatment.

For instance,

• In August 2018, Krystal Biotech received orphan drug designation for its product candidate KB105 indicated for treatment of ichthyosis in paitent diagnosed with deficiency of transglutaminase 1 (TGM-1). This designation boosted the company’s research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Lamellar ichthyosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Lamellar Ichthyosis Market Share Analysis

Lamellar ichthyosis market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to lamellar ichthyosis market.

Основными игроками на рынке пластинчатого ихтиоза являются Timber Pharmaceuticals LLC, Patagonia Pharmaceuticals, LLC, Galderma, Mayne Pharma Group Limited, Krystal Biotech, LGM Pharma, ANAPTYSBIO, INC., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries, Inc., Teva Pharmaceuticals USA, Inc., Biophore, Sonneborn LLC, Genentech, Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina, Inc, Natera Inc., ELITech Group, ThermoFisher Scientific, Inc., Danaher, PerkinElmer, Inc., Abcam plc, Merck KGaA и другие отечественные и мировые игроки. Аналитики DBMR понимают конкурентные преимущества и предоставляют конкурентный анализ для каждого конкурента отдельно.

SKU-61103